P
Pedro L. Silva
Researcher at Federal University of Rio de Janeiro
Publications - 164
Citations - 2700
Pedro L. Silva is an academic researcher from Federal University of Rio de Janeiro. The author has contributed to research in topics: Lung & Lung injury. The author has an hindex of 25, co-authored 137 publications receiving 1772 citations. Previous affiliations of Pedro L. Silva include Ministry of Science, Technology and Innovation & National Institute of Standards and Technology.
Papers
More filters
Journal ArticleDOI
Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies
Miquéias Lopes-Pacheco,Pedro L. Silva,Fernanda F. Cruz,Denise Battaglini,Chiara Robba,Paolo Pelosi,Marcelo M. Morales,Celso Caruso Neves,Patricia R. M. Rocco +8 more
TL;DR: In this paper, the authors summarize the major features of SARS-CoV-2 biology and the current understanding of COVID-19 pathogenesis, as well as its clinical repercussions in the lung, heart, kidney, bowel, liver, and brain.
Journal ArticleDOI
Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial.
Patricia R. M. Rocco,Pedro L. Silva,Fernanda F. Cruz,Marco Antonio C. M. Junior,Paulo Fernando Guimarães Morando Marzocchi Tierno,Marcos de Assis Moura,Luis Frederico Gerbase De Oliveira,Cristiano Cleidson Lima,Ezequiel Aparecido Dos Santos,Walter Freitas Junior,Ana Paula Salles Moura Fernandes,Kleber G. Franchini,Erick Magri,Nara Franzin de Moraes,Jose Mario de Jesus Goncalves,Melanie Nogueira Carbonieri,Ivonise Sampaio Dos Santos,Natalia de Fatima Paes,Paula Veronica Martini Maciel,Raissa Prado Rocha,Alex Fiorini de Carvalho,Pedro Augusto Alves,José Luiz Proença Modena,Artur T. Cordeiro,Daniela Barreto Barbose Trivella,Rafael Elias Marques,Ronir Raggio Luiz,Paolo Pelosi,José Roberto Lapa e Silva +28 more
TL;DR: In this paper, a multicenter, randomized, double-blind, placebo-controlled trial, adult patients presenting up to 3 days after onset of Covid-19 symptoms (dry cough, fever, and fatigue) were enrolled.
Journal ArticleDOI
Immunomodulation after ischemic stroke: potential mechanisms and implications for therapy
TL;DR: The modifications in local and systemic immunity that occur after stroke are described, mechanisms of stroke-induced immunosuppression and their role in pneumonia are outlined, and potential therapeutic targets to reduce post-stroke complications are highlighted.
Journal ArticleDOI
Albumin versus crystalloid solutions in patients with the acute respiratory distress syndrome: a systematic review and meta-analysis
Christopher Uhlig,Pedro L. Silva,Pedro L. Silva,Stefanie Deckert,Jochen Schmitt,Marcelo Gama de Abreu +5 more
TL;DR: Based on the findings of this review, colloid therapy with albumin improved oxygenation but did not affect mortality, suggesting a high need for RCTs investigating the effects of colloids in ARDS patients.
Posted ContentDOI
Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial
Patricia R. M. Rocco,Pedro L. Silva,Fernanda F. Cruz,Marco Antonio C. M. Junior,Paulo Fernando Guimarães Morando Marzocchi Tierno,Marcos de Assis Moura,Luis Frederico Gerbase De Oliveira,Cristiano Cleidson Lima,Ezequiel Aparecido Dos Santos,Walter Freitas Junior,Ana Paula Morais Fernandes,Kleber G. Franchini,Erick Magri,Nara Franzin de Moraes,Jose Mario de Jesus Goncalves,Melanie Nogueira Carbonieri,Ivonise Sampaio Dos Santos,Natalia de Fatima Paes,Paula Veronica Martini Maciel,Raissa Prado Rocha,Alex Fiorini de Carvalho,Pedro Augusto Alves,José Luiz Proença Modena,Artur T. Cordeiro,Daniela B. B. Trivella,Rafael Elias Marques,Ronir Raggio Luiz,Paolo Pelosi,José Roberto Lapa e Silva +28 more
TL;DR: In patients with mild Covid-19, symptom resolution did not differ between the nitazoxanide and placebo groups after 5 days of therapy, however, early nitaz oxanide therapy was safe and reduced viral load significantly.